Yes, obviously dendritic cell therapy is one potential approach worthy of study, particularly as a means to address immunologically cold tumors.
That observation misses the point entirely, though.
Furthermore, the fact that dendritic cell therapy as a platform could be one potential solution to this challenge (which remains to be proven, so remains very much in speculation) does not mean NWBO is necessarily appropriate for all but the most risk-tolerant investors.
Market Data 
Markets 
AI
